Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Contineum Therapeutics Inc (CTNM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.81-10.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CTNM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve operating income | A supporting condition in Contineum Therapeutics Inc's published investment case. The stated target is operating losses reduce by at least 10% YoY. | Intact | operating losses do not improve or worsen in FY26 | Operating income: $-20.966M FY2026-Q3; GAAP. Published target: operating losses reduce by at least 10% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 2026-20,966,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative growth, meaning the business depends on future clinical progress rather than established profits. The long-term thesis is on watch: management has made progress on stated priorities, but recent financial performance is weak and overall evidence confidence is low.
The evidence gives no valuation level or clear account of market expectations, so whether CTNM looks cheap, fair, or expensive versus peers is unclear. No fragility signals were identified, but that does not resolve the uncertainty around expectations.
Near term, the company remains loss-making, though its net loss improved modestly and research and development expenses fell year over year. Management reports ongoing enrollment in a Phase 2 IPF trial, positive early chronic-pain data, and cash runway through mid-2029, while operating costs remain high. The next results carry elevated miss risk, and weaker guidance would add pressure to the business outlook.
Over the multi-year view, the key test is whether PIPE-791 clinical development produces evidence strong enough to support further progress in IPF and chronic pain. Cash discipline and continued control of expenses also matter. Near term, guidance, employment data, and results from major Healthcare companies are cited as swing factors, though the evidence for their effect on CTNM is limited.
CTNM has some clinical and cash-runway progress, but it remains loss-making, high risk, and below its industry cohort in recent performance. The 1-3 year thesis depends on trial progress and disciplined spending. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Achieve positive cash flow from operations |
| The company is focused on achieving positive cash flow from operations, currently at -$16.27M. |
| Broken |
| cash flow from operations remains negative over next 4 quarters |
Cash from operations: $-11.501M FY2026-Q2; GAAP. Published target: >= $0 positive cash flow. Target period is not explicitly aligned with this observation. Jul 30, 2026-11,501,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce net income losses | Net income improved slightly to -$14.46M in 2026-Q1. | Improving | net income losses do not improve or worsen in FY26 | Net income: $-18.697M FY2026-Q3; GAAP. Published target: net losses decrease by at least 10% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 2026-18,697,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.81 → $-2.00 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-07-25 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-07-26 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-07-27 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-07-28 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-07-29 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-07-30 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-07-31 | $-1.81 | $11,000,000 | 7 / 1 |
| 2026-08-01 | $-1.81 | $2,200,000 | 5 / 2 |
| 2026-08-02 | $-1.82 | $1,833,330 | 7 / 6 |
| 2026-08-03 | $-1.82 | $1,833,330 | 7 / 6 |
| 2026-08-04 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-05 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-06 | $-1.82 | $1,833,330 | 7 / 6 |
| 2026-08-07 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-08 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-09 | $-1.82 | $1,833,330 | 7 / 6 |
| 2026-08-10 | $-1.82 | $1,833,330 | 7 / 6 |
| 2026-08-11 | $-1.82 | $1,833,330 | 7 / 6 |
| 2026-08-12 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-13 | $-1.82 | $1,833,330 | 7 / 6 |
| 2026-08-14 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-15 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-16 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-17 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-18 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-19 | $-1.82 | $2,200,000 | 5 / 4 |
| 2026-08-20 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-21 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-22 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-23 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-24 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-25 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-26 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-27 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-28 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-29 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-30 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-08-31 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-01 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-02 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-03 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-04 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-05 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-06 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-07 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-08 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-09 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-10 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-11 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-12 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-13 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-14 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-15 | $-1.80 | $2,200,000 | 5 / 4 |
| 2026-09-16 | $-1.84 | $2,200,000 | 5 / 4 |
| 2026-09-17 | $-1.84 | $2,200,000 | 5 / 4 |
| 2026-09-18 | $-1.84 | $2,200,000 | 5 / 4 |
| 2026-09-19 | $-1.84 | $2,200,000 | 5 / 4 |
| 2026-09-20 | $-1.84 | $2,200,000 | 5 / 4 |
| 2026-09-21 | $-1.84 | $2,200,000 | 5 / 4 |
| 2026-09-22 | $-1.94 | $2,200,000 | 5 / 4 |
| 2026-09-23 | $-1.94 | $2,200,000 | 5 / 4 |
| 2026-09-24 | $-1.94 | $2,200,000 | 5 / 4 |
| 2026-09-25 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-09-26 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-09-27 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-09-28 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-09-29 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-09-30 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-01 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-02 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-03 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-04 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-05 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-06 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-07 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-08 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-09 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-10 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-11 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-12 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-13 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-14 | $-1.99 | $2,200,000 | 5 / 4 |
| 2026-10-15 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-16 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-17 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-18 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-19 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-20 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-21 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-22 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-23 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-24 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-25 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-26 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-27 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-28 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-29 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-30 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-10-31 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-11-01 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-11-02 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-11-03 | $-2.00 | $2,200,000 | 5 / 4 |
| 2026-11-04 | $-2.00 | $2,200,000 | 5 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
0 raises · 1 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.